
Non-Sponsored Content
Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
By: News Feed | Last updated: 28th September 2018 | In: Cardiovascular
Article Keywords
Abbott, aortic stenosis, Heart Failure, NYHA, Portico, TAVR, TCT 2018
Transcatheter aortic valve replacement (TAVR) with the Portico® valve (Abbott) was found to be safe and associated with low rates of stroke, death or paravalvular leakage at one-year follow-up, according to the real-world PORTICO I study in patients with symptomatic, severe aortic stenosis. The one-year results were presented during the 30th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium held in San Diego from 21-25 September 2018 with simultaneous publication in the Journal of the American College of Cardiology (JACC).
“Portico® offers physicians the ability to safely and successfully treat patients suffering from symptomatic, severe aortic stenosis with a high-level of confidence. These one-year results in a real-world setting give us assurance that Portico® is an excellent and important treatment option for patients with severe aortic stenosis who are at increased risk for open-heart surgery.” said Lars Søndergaard, M.D., DMSc, Rigshospitalet, Copenhagen, Denmark and principal investigator of the trial.
The ongoing, prospective, long-term, real-world, international, multicenter, PORTICO I trial (NCT01802788) recruited 941 symptomatic, severe aortic stenosis patients at high-risk for open-heart surgery. All participants were treated with the self-expanding, repositionable Portico® TAVR system via a transfemoral access. The primary objective of the study was to investigate the all-cause mortality at one year. Secondary objectives included the device performance, the improvement in functional capacity, and the adverse event (AE)-rates observed at 30 days and one-year post placement, and annually thereafter for up to five years.
The one-year results of the PORTICO I study indicated that patients who received a Portico® valve had low rates of all-cause mortality (12.1%), cardiovascular mortality (6.6%), disabling stroke (2.2%), and myocardial infarction (2.5%). Participants had significantly improved haemodynamic performance. The mean aortic valve area increased from 0.72 cm2 (±0.37 cm2) at baseline to 1.79 cm2 (±0.48 cm2) at 30 days (1.79 ± 0.48 cm2) which was sustained at the one-year mark, measuring 1.74 cm2 (±0.49 cm2). Moderate paravalvular leak decreased from 3.9% of patients at 30 days to 2.6% of patients at one year. The proportion of patients classified with NYHA Class III/IV heart failure decreased from 63.8% at baseline to 7.7% after one year.
References
Søndergaard L, et al. J Am Coll Cardiol. 2018; DOI: 10.1016/j.jacc.2018.09.014
Newsletter Sign-Up
Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.
Newsletter Sign-Up
YOU MAY ALSO LIKE




Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd. – Febuxostat prevents CV events in hyperuricaemia patients
YOU MAY ALSO LIKE




















© Copyright 2018 MediPaper Medical Communications Ltd. – Febuxostat prevents CV events in hyperuricaemia patients
Leave a Reply
Want to join the discussion?Feel free to contribute!